Ke Shu-Jun, Wang Peng, Xu Bing
Department of Radiology, Shanghai Punan Hospital of Pudong New District, Shanghai 200215, China,
Department of Radiology, Changzheng Hospital, Naval Medical University, Shanghai 200003, China.
Cancer Manag Res. 2019 Jan 22;11:1003-1012. doi: 10.2147/CMAR.S187370. eCollection 2019.
Clear cell adenocarcinoma of the lung (CCAL) is a rare diagnosis with poorly understood clinicopathological characteristics and disease progression.
A population cohort study was conducted using prospectively extracted data from the Surveillance, Epidemiology and End Results database for patients with histological diagnoses of CCAL. Propensity-matched analysis was performed for survival analysis.
A total of 1,203 patients with CCAL were included. The median overall survival (OS) for all patients was 19.0 months (95% CI 16.0-22.0 months). Data for 1-, 3-, and 5-year OS were 58.7, 37.3, and 27.7%, respectively. Log-rank analysis showed that the prognoses of CCAL patients were better than those with non-CCAL adenocarcinoma after propensity-matched analysis (<0.001). Cancer-directed surgery significantly improved median OS by almost 40 months (45.0 vs 5.0 months; <0.01). Radiotherapy after surgery prolonged survival compared with patients who only received surgery (37.0 vs 17.0 months; <0.01). Multivariate Cox analysis showed that older age (>65 years), larger lesions, and lymph node and distant metastases were independent prognostic factors for worse survival, while cancer-directed surgery was an independent protective factor. Five independent prognostic factors were identified and entered into the nomogram. The concordance index of the nomogram for predicting survival was 0.72 (95% CI 0.69-0.74). The calibration curves for the probability of 3-, 5-, and 10-year OS showed optimal agreement between nomogram prediction and actual observation.
CCAL is a rare pathology, and older age, larger lesions, metastases, and cancer-directed surgery were associated with prognosis. A prognostic nomogram was established to provide individual prediction of OS.
肺透明细胞腺癌(CCAL)是一种罕见的诊断,其临床病理特征和疾病进展了解甚少。
采用前瞻性提取的监测、流行病学和最终结果数据库中组织学诊断为CCAL患者的数据进行人群队列研究。进行倾向匹配分析以进行生存分析。
共纳入1203例CCAL患者。所有患者的中位总生存期(OS)为19.0个月(95%CI 16.0 - 22.0个月)。1年、3年和5年OS数据分别为58.7%、37.3%和27.7%。对数秩分析显示,倾向匹配分析后,CCAL患者的预后优于非CCAL腺癌患者(<0.001)。针对癌症的手术显著改善了中位OS,延长了近40个月(45.0对5.0个月;<0.01)。与仅接受手术的患者相比,术后放疗延长了生存期(37.0对17.0个月;<0.01)。多因素Cox分析显示,年龄较大(>65岁)、病灶较大、淋巴结和远处转移是生存较差的独立预后因素,而针对癌症的手术是独立的保护因素。确定了五个独立预后因素并纳入列线图。预测生存的列线图一致性指数为0.72(95%CI 0.69 - 0.74)。3年、5年和10年OS概率的校准曲线显示列线图预测与实际观察之间具有最佳一致性。
CCAL是一种罕见的病理类型,年龄较大、病灶较大、转移和针对癌症的手术与预后相关。建立了预后列线图以提供OS的个体预测。